Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US03843E1047
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00L9HP0Z0
AQST
Aquestive Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Drug Manufacturers - Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Aquestive Therapeutics Inc
ISIN
US03843E1047
TICKER
AQST
MIC
XNAS
REUTERS
AQST.OQ
BLOOMBERG
AQST US
Sun, 26.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.04.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 23, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Aquestive Therapeutics
US03843E1047

Important Information Regarding Section 20(a) Individual Liability ClaimsNEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual defendant in a pending securities c...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 22, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates in...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 22.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Aquestive Therapeutics
US03843E1047

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innova...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 19.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sat, 18.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Aquestive Therapeutics
US03843E1047

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA? NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ: AQST) risk disclosures during the period from June 16, 2025 through January 8, 2026. Shareholders who lost money on AQST stock may find out if you...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If yo...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       Aquestive Therapeutics
US03843E1047

Wall Street Reassessment: Analyst Opinion Evolution on AQSTNEW YORK, April 15, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) from $15 to $8, warning that "the history of CRLs following similar letters increases the risk of a potential delay for Anaphylm." Shareholders who pu...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP:Do you, or did you, own shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST)?Did you purchase your shares between June 16, 2025 and January 8, 2026, inclusive?Did you lose money in your investment in Aquestive Therapeutics, Inc.?Do you want to discuss your rights?Bernst...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encou...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you pur...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The Aques...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encour...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates incl...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Aquestive Therapeutics
US03843E1047

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Aquestive Therapeutics
US03843E1047

New York, New York--(Newsfile Corp. - April 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purc...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Aquestive Therapeutics
US03843E1047

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e...
Read more
Aquestive Therapeutics
Technical Analysis Termsheets Terminal
Permalink